HealthMore in Health →
Beeline Medicines Launches With Five Bristol Myers Assets and Bain Capital Backing
Bain Capital has officially launched Beeline Medicines with five assets from Bristol Myers Squibb, creating a new biotech centered on shelved immunology drugs.
Key Takeaways
- Beeline Medicines launched with five assets sourced from Bristol Myers Squibb.
- The company is backed by a Bain Capital model the source says has worked before.
DE
DT Editorial AI··via endpoints.news